1月23日早盘，港股通创新药板块强势反弹，高弹性港股通创新药ETF（520880）急速冲上2%！成份股 方面，云顶新耀、映恩生物-B领衔涨势，权重股康方生物涨超5%。 消息面，1月22日，商务部联合国家发展改革委、国家医保局等9部门印发《关于促进药品零售行业高质 量发展的意见》，明确提出鼓励创新药、参比制剂等进入零售药店销售渠道，并推动电子处方流转平台 建设，支持实体医疗机构与互联网医院与零售药店对接，优化购药体验。 分析人士指出，该政策旨在强化药品零售端的专业服务功能，提升创新药可及性，尤其为高值创新药 （如CAR-T）通过商保目录补充医保保障缺口提供落地路径。 二级市场资金提前埋伏，此前港股通创新药板块连阴6日，资金频频借道港股通创新药ETF（520880） 逢跌吸筹。数据显示，本周以来，520880累计获超2.3亿元资金净申购，最新份额升至45.38亿份，续创 历史新高！ 一键投资创新药，认准高弹性T+0利器——港股通创新药ETF（520880）及其场外联接基金 （025221），其跟踪的恒生港股通创新药精选指数具备三大独特优势，配置价值突出： 1、纯粹，全面。不含CXO，纯正创新药！全面覆盖创新药研发 ...

机构：东吴证券 研究员：朱国广/邹行健 考虑到2025 年公司有多款ADC 新管线完成临床前研发，我们提高了对研发费用的预测水平，相应影响 归母净利润水平，2025-2026 年归母净利润分别下调为-1.15/-0.97 亿元，原值为0.14/0.63 亿元，新增 2027年归母净利润预测为-0.26 亿元。随着公司后续产品KN026 有望国内上市，JSKN003 也即将申报上 市，我们预计未来公司亏损将逐步缩小。 多款核心管线催化剂密集，KN026 已提交上市申请：KN026 是公司开发的HER2 双表位单抗，其核心 适应症之一的联合化疗治疗2L 及以上胃癌目前已经获得NMPA 受理，我们预计2026 年年底或2027 年有 望获批上市。公司已经将该产品的国内权益授予石药集团，未来上市后石药集团将负责相关商业化工 作，公司将保留KN026 的独家生产权，为石药集团提供产品。除此之外KN026 的乳腺癌1L 治疗和新辅 助治疗的方案也有望在2026 年提交上市申请。JSKN003 是公司开发的首款ADC管线，其临床进展也较 为迅速，针对2L HER2 阳性乳腺癌的适应症预计有望在2026 年提交国内上市申请。 ...

Core Viewpoint - The company, XinNuoWei, is undergoing a significant transformation from a traditional caffeine producer to an innovative pharmaceutical platform, resulting in substantial financial losses for 2025, with projected losses between 170 million to 255 million yuan, marking a drastic decline compared to the previous year's profit of 53.73 million yuan [6]. Financial Performance - The net profit attributable to shareholders is expected to be a loss of 170 million to 255 million yuan, a decline of 416% to 575% compared to the same period last year [6]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 210 million to 315 million yuan, a decrease of 596% to 844% year-on-year [6]. R&D Investment - The company plans to invest approximately 1 billion yuan in R&D for the year 2025, an increase of 18.76% year-on-year, which is the primary reason for the financial losses [4]. - The R&D spending has led to significant milestones, including the approval of four antibody drugs, six ADC products, and one mRNA vaccine for clinical trials [4]. - High R&D expenditure is common during the transformation phase of pharmaceutical companies, with leading international firms often exceeding 30% in R&D expense ratios [4]. Traditional Business Challenges - The traditional functional raw materials business, primarily caffeine products, has seen increased sales but a significant decline in gross margins due to market conditions, leading to reduced profit contributions [5]. - The company is experiencing a "transition phase" where the old business model is losing momentum while the new innovative pipeline is still developing [8]. Strategic Moves - XinNuoWei has initiated a dual strategy by applying for a listing on the Hong Kong Stock Exchange and establishing a joint venture focused on GLP-1 drugs, aiming to alleviate financial pressures and enhance its market position [10]. - The joint venture will focus on the GLP-1 market, which is expected to face intense competition and pricing pressures as multiple companies are preparing to launch similar products [12]. Future Outlook - The success of the innovative drug segment in reversing the current financial situation remains uncertain and will require time to validate [10]. - The company’s ability to leverage its GLP-1 assets and maintain R&D funding while navigating a competitive landscape will be critical for its future profitability [12].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector has experienced a continuous adjustment for six days, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a decline of 0.75% and a trading volume of 200 million [1]. Group 1: Market Performance - The innovative drug ETF (520880) is fully invested in innovative drug R&D companies and has recently attracted significant capital inflows, indicating a potential opportunity for investment in innovative drugs [3][12]. - The leading pharmaceutical companies are expected to have promising earnings forecasts for 2025, which could lead to valuation recovery opportunities [3][12]. - The ETF has seen a recent increase in fund size to 2.348 billion, with the number of shares reaching 4.382 billion, both hitting new highs since its listing [4][10]. Group 2: Long-term Outlook - The core logic of the Hong Kong Stock Connect innovative drug sector remains solid, with expectations of a total overseas licensing amount for innovative drugs reaching 135.7 billion in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][12]. - The National Medical Products Administration (NMPA) is expected to approve 76 innovative drugs in 2025, leading the world in approvals, and will continue to optimize the review and approval process for innovative drugs [3][12]. - Investment strategies from Zhongtai International and Guosen Securities recommend continued focus on the innovative drug sector for 2026 [3][12]. Group 3: ETF Characteristics - The ETF exclusively covers innovative drug R&D companies, excluding CXO, and has a significant concentration in leading companies, with the top ten innovative drug companies accounting for over 73% of the weight [5][12]. - The ETF employs a strategy to reduce the weight of less liquid component stocks, effectively managing tail risks [6][12]. - The ETF's tracking index has a notable advantage with a high concentration of leading companies, enhancing its investment value [7][12].

Core Viewpoint - The approval of the Upaftin sustained-release tablet application by Shijiazhuang Four Medicines adds to the competitive landscape of the JAK1 inhibitor market, which is rapidly growing and attracting local pharmaceutical companies [1]. Group 1: Market Potential - Upaftin sustained-release tablets, developed by AbbVie, are projected to reach nearly $6 billion in global sales by 2024, with a significant presence in the Chinese market after being included in the national medical insurance list [1][2]. - The sales of Upaftin in the Chinese hospital market are expected to exceed 300 million yuan in 2024, marking a year-on-year growth of 278.02%. By the first three quarters of 2025, sales are anticipated to surpass 400 million yuan, reflecting a staggering year-on-year increase of 104.03% [1][2]. Group 2: Patent Challenges - The core compound and composition patents for Upaftin were originally set to expire in 2030. However, a significant turning point occurred at the end of 2022 when Sichuan Guowei initiated a patent challenge targeting the compound patent [4][7]. - In July 2023, the National Intellectual Property Administration declared the compound patent invalid, significantly opening the pathway for generic manufacturers six years earlier than expected [7]. Group 3: Competitive Landscape - Over 35 companies, including Shijiazhuang Four Medicines, have submitted applications for the generic version of Upaftin, indicating intense competition among leading generic drug manufacturers [8]. - Despite early submissions by companies like Sichuan Guowei and Tiandi Hengyi, no local company has yet successfully launched a generic version, with AbbVie still holding a dominant position in the market [10][12].

Core Viewpoint - The article discusses the recruitment of participants for a Phase III clinical trial evaluating the efficacy and safety of CM326, a recombinant humanized monoclonal antibody injection, in moderate to severe asthma patients [1][3]. Group 1: Background Information - The clinical trial is approved by the National Medical Products Administration (Approval No: 2021LP00315) and has been reviewed by the hospital clinical trial ethics committee [1][3]. - Participants will receive the study drug, examination costs, and a certain amount of compensation for their participation [1][3]. Group 2: Inclusion Criteria - Participants must be aged between 18 and 80 years and weigh at least 40 kg [4]. - Lung function tests must show that the forced expiratory volume in one second (FEV1) is ≤80% of the predicted value [4]. - Participants must have a positive bronchodilator test within 24 months prior to signing informed consent [5]. - They should have been on a stable treatment regimen of medium to high doses of inhaled corticosteroids combined with at least one control medication for at least 3 months prior to screening [5]. - Participants must have experienced at least one severe asthma exacerbation in the 12 months prior to signing informed consent, but none in the 30 days before signing [5]. Group 3: Research Centers - The trial will be conducted across multiple hospitals, including Shanghai Jiao Tong University Affiliated Ruijin Hospital, Shanghai Tongji Hospital, and Jilin University First Hospital, among others [2][6]. - A total of 44 research centers are listed, indicating a broad geographical reach for participant recruitment [6][7].

数据来源：wind 进一步展望生物科技领域的投资前景。大家已经了解，港股为生物科技公司上市提供了得天独厚的条 件，那么当前为何要投资港股的生物科技公司？这可以从宏观背景层面进行分析。当前美联储正处于降 息周期，大家也清楚，在降息环境下，包括美国在内的境外资金更倾向于流出美股市场，转而寻找具有 成长价值的投资机会，而非停留在美股市场追求低息无风险收益，而港股很可能成为其优先选择。 在美联储新一轮防御式降息周期中，港股资产展现出比以往更优的收益弹性和流动性前景。这对于以港 股生物科技为代表的成长板块的估值修复和业绩增长，具有重要的指引意义。下方列出的时间序列图 表，重点标记了恒生生物科技指数与美联储降息周期时间节点的重要关联。可以看到，2019年7月至 2020年美联储降息期间，恒生生物科技指数就展现出了较好的业绩弹性。而从2024年至2025年年底，乃 至如今迈入2026年，在降息周期的大背景下，恒生生物科技指数很可能展现出更优的收益弹性表现。这 是我们从宏观政策角度分析得出的结论。 回归国内政策层面，未来境内尤其是港股上市的生物科技公司将获得哪些政策支持？我们能看到，行业 政策正全链条支持创新药发展。其中一个 ...

Core Viewpoint - The innovative drug sector is expected to experience a resurgence in 2025, transitioning from a broad market rally to a focus on select stocks driven by global clinical data, overseas commercialization, and domestic profitability turning points [1] Group 1: Market Performance - In 2025, the A-share innovative drug index saw an annual increase of nearly 20%, while the H-share index rose by 66.52%. The first half of the year recorded increases of approximately 17% for A-shares and 58% for H-shares, with the second half showing more modest gains of about 3% and 9% respectively [1] - The A-share billion-dollar club includes companies like BeiGene (市值4190.64亿元), Hengrui Medicine (市值3994.27亿元), and Baillie Gifford (市值1332.18亿元), while the H-share club includes Hengrui Medicine (市值4729.34亿元), BeiGene (市值3191亿元), and others [2] Group 2: Company Dynamics - Companies in the billion-dollar club are valued based on "pipeline value + BD monetization + global sales peak." Capital markets are comparing these firms to global leaders, elevating them from "First-in-class" to "Best-in-class" [3] - In 2025, domestic innovative drug license-out transactions totaled 83, amounting to $84.5 billion, surpassing the total of over $60 billion for 2024. Hengrui Medicine's international deals included partners like GSK and Merck, with upfront payments totaling $765 million [3] Group 3: Market Challenges - Some companies that previously entered the billion-dollar club, such as Kintor Pharmaceutical and China National Pharmaceutical Group, have fallen below the threshold due to systemic valuation corrections and stricter FDA approval standards [4] - The market has become desensitized to BD transactions, as evidenced by the stock price drop of Innovent Biologics following a $11.4 billion collaboration announcement, indicating a tightening of valuation expectations [4] Group 4: Capital Operations - As the innovative drug market heats up in 2025, companies are initiating new capital operations, including acquisitions and cross-border listings. For instance, China National Pharmaceutical Group acquired Lixian Pharmaceuticals for approximately $500 million [5] - Baillie Gifford raised 3.764 billion yuan through a private placement in the A-share market, while also applying for an IPO in Hong Kong [5] Group 5: Small-cap Stocks - The top three performing innovative drug stocks in A-shares for 2025 were Shuyou Pharmaceutical (涨幅488%), Yipinhong (涨幅370%), and Yifang Biotechnology (涨幅235%). In H-shares, the top performers were Beihai Kangcheng (涨幅1824%), Heber Pharmaceuticals (涨幅553%), and Sanofi (涨幅311.18%) [7] - These stocks have core products that received high recognition, with clinical pipelines achieving significant breakthroughs, such as Shuyou's STSP-0601 and Beihai Kangcheng's Selinexor [7] Group 6: Future Outlook - The innovative drug sector is expected to enter a "hardcore alpha" phase in 2026, focusing on companies that can deliver genuine clinical data, achieve overseas commercialization, and demonstrate domestic profitability [10] - The emphasis will shift from broad market rallies to specific companies that can prove their clinical trial results and secure sales milestones, with a focus on high-demand areas like dual antibodies and ADCs [11][12]

Core Viewpoint - New Nuo Wei (300765.SZ), a subsidiary of Shijiazhuang Yiling Pharmaceutical, is projected to incur a significant loss of between 170 million to 255 million yuan in 2025, marking a stark decline of 416% to 575% compared to the previous year's profit of 53.726 million yuan, indicating a dramatic shift from a peak net profit of over 700 million yuan in 2023 to its first annual loss in six years [2][13]. Group 1: Financial Performance - The anticipated net loss for 2025, excluding non-recurring gains and losses, is expected to be between 210 million to 315 million yuan, representing a decline of 596% to 844% from the previous year's profit of 42.342 million yuan [2][13]. - The company is experiencing a significant increase in research and development (R&D) expenditure, projected at approximately 1 billion yuan for 2025, which is an 18.76% increase year-on-year, contributing to the financial losses [5][16]. - The fourth quarter of 2025 is expected to see a substantial increase in losses, with estimated net losses ranging from 146 million to 231 million yuan, indicating a continuous decline in profitability over five consecutive quarters [7][18]. Group 2: Strategic Transition - New Nuo Wei is undergoing a strategic transformation from a traditional caffeine product leader to an innovative pharmaceutical platform, which involves substantial R&D investments aimed at expanding its drug pipeline [3][14]. - The company has achieved significant milestones in its R&D pipeline, including the approval of four antibody drugs, six ADC products, and one mRNA vaccine for clinical trials, reflecting a proactive approach to future growth despite current losses [5][16]. - The acquisition of an 80% stake in its subsidiary, Jushi Bio, for 1.1 billion yuan has increased the financial burden, as Jushi Bio is not yet profitable and its losses are now more pronounced in New Nuo Wei's financial statements [6][17]. Group 3: Market Position and Future Prospects - New Nuo Wei has submitted an application for a Hong Kong IPO under the name "Shijiazhuang Innovation," aiming to alleviate financial pressures and support its innovative drug business [19]. - The establishment of a joint venture focused on GLP-1 assets is part of a broader strategy to penetrate the weight loss and diabetes market, with the company investing approximately 158 million yuan for a 35% stake [22]. - The competitive landscape for GLP-1 drugs is intensifying, with over 30 competing products in the pipeline, raising concerns about market share and profitability for New Nuo Wei's upcoming products [23].

Group 1 - The Hong Kong Innovation Drug ETF (159570) has seen a significant inflow of funds, with a recent trading volume exceeding 5 billion yuan and a net inflow of over 300 million yuan in the past five days [1] - As of January 20, the total size of the Hong Kong Innovation Drug ETF reached over 25.3 billion yuan, leading the market in terms of scale among innovation drug ETFs [1] - The index components of the ETF showed mixed performance, with notable gains from companies like Kingsoft Biotech and China Biologic Products, while companies like CanSino Biologics experienced declines [3][4] Group 2 - At the J.P. Morgan Healthcare Conference, several Chinese pharmaceutical companies showcased their advancements, including BeiGene's new drug approval in China and plans for accelerated approval in the U.S. [5] - Innovent Biologics and Pfizer are set to conduct five global Phase III trials for their drug SSGJ-707 by 2026, targeting various cancers [6] - The collaboration between NVIDIA and Eli Lilly aims to establish an AI innovation lab with a projected investment of up to 1 billion USD over five years, potentially transforming drug development processes [8] Group 3 - Tempus AI reported a revenue of approximately 1.27 billion USD for 2025, marking an 83% year-on-year increase, driven by significant growth in its diagnostic business [9] - The top ten components of the Hong Kong Innovation Drug ETF account for over 73% of its weight, highlighting the concentration of leading innovative drug companies within the ETF [10]